DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis

DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis

Abstract Background Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Current TB treatments are inadequate, requiring participants closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated. In addition to these well-recognized shortcomings, cur...

Full description

Saved in:
Bibliographic Details
Main Authors: Nestani Tukvadze, Sehlomola Mashatole, Anne Jacobs, Tlhago Ngwanto, Norbert Heinrich, Annelies Van Rie, Valeriu Crudu, Elena Tudor, Leila Goginashvili, Elmira Ibraim, Celso Khosa, Pauline Howell, Shakira Rajaram, Kinita Naidoo, Stefan Niemann, Klaus Reither, Robert S. Wallis
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Infectious Diseases
Subjects:
Tuberculosis
Drug Resistant Tuberculosis (DR-TB)
Rifampicin-resistant tuberculosis (RR-TB)
Host-directed therapies
Clinical trial
Metformin
Online Access:https://doi.org/10.1186/s12879-025-11072-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12879-025-11072-5

Similar Items